National Resilience, a biotech company, agreed to acquire bio-manufacturing plant in Allston from Sanofi, a French multinational pharmaceutical company. Financial terms were not disclosed. “We created Resilience to reimagine biopharmaceutical manufacturing through unprecedented investment in technology and a best-in-class team to execute our vision. Covid-19 has exposed critical vulnerabilities in medical supply chains, and today’s manufacturing can’t keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale. We are committed to tackling these huge problems with a whole new business model," Robert Nelsen, Resilience Founder and Chairman of the Board.